Genetic Medicines’ Path to Scalability for Patients and Investors
Monday, February 26, 2024
Majestic Complex
More than 30 genetic medicine treatments have been approved by the FDA so far, with hundreds more in the clinical pipeline, but companies working in these newer modalities have been challenged by scaling up manufacturing and establishing reliable reimbursement paths. This panel will examine the risks and opportunities when commercializing genetic medicines and how best to fulfill the expectations of investors to support bringing these pioneering benefits to patients.
Speakers
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}